Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.55 |
| ▸ | NPC1 | O15118 | 8/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | TP53 | P04637 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | RAF1 | P04049 | 1/20 | 0.53 |
| ▸ | ARAF | P10398 | 1/20 | 0.53 |
| ▸ | BRAF | P15056 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1455377 | 0.90 | KMT2A (0.54) | RAB9ANPC1SMN1; SMN2HDAC1BRAF | |
| SCHEMBL1456181 | 0.90 | AR (0.58) | RAB9ANPC1SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL1455101 | 0.86 | PNLIP (0.46) | HDAC1BRAFNAMPTKMT2AMEN1 | |
| SCHEMBL1454267 | 0.86 | NPC1 (0.47) | RAB9ANPC1SMN1; SMN2TP53HDAC1 | |
| SCHEMBL1454431 | 0.85 | TRPV1 (0.50) | RAB9AHDAC1RAF1ARAFBRAF | |
| SCHEMBL1453961 | 0.85 | NAMPT (0.46) | TP53HDAC1RAF1ARAFBRAF | |
| SCHEMBL7079625 | 0.85 | RAB9A (0.73) | RAB9ANPC1SMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL1456027 | 0.85 | KCNK3 (0.48) | RAB9ANPC1TP53HDAC1BRAF | |
| SCHEMBL1455972 | 0.85 | HDAC3 (0.46) | RAB9ARAF1BRAFRXFP1KDM4E | |
| SCHEMBL1455538 | 0.84 | USP2 (0.60) | RAB9ANPC1SMN1; SMN2ALDH1A1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979348-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-01-18 | — | — | EP | disclosed |
| US-7910595-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2011-03-22 | — | — | US | disclosed |
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | RAB9A 571/4885NPC1 37/4885SMN1; SMN2 3135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.